Date Added: 15/03/2017
Date Updated: 15/03/2017
Nivolumab with ipilimumab for advanced non-small cell lung cancer – first line
Specialties: Oncology & radiotherapy
Technology Type: Drugs
Stage of development: Investigational - phase III
Stage of EAA: Prioritised for assessment
Non-small cell lung cancer (NSCLC).
Squamous or non-squamous histology.
Stage of disease
Stage IV or recurrent.
Place in Treatment